Cue Biopharma to Host Virtual Investor Event on May 15, 2025

Core Insights - Cue Biopharma is hosting a virtual investor event on May 15, 2025, to discuss its innovative biologics platform aimed at treating autoimmune diseases and cancer [1][2] - The event will feature key opinion leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD, who will provide insights into the company's differentiated biologics platform and its clinical trials [2][3] Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics that selectively engage and modulate disease-specific T cells [1][8] - The company's proprietary platform, Immuno-STAT™, is designed to harness the body's immune potential without the adverse effects of broad systemic immune modulation [8][9] Clinical Programs - The event will include a review of the CUE-400 series, highlighting new preclinical proof-of-concept data for lead candidate CUE-401, which aims to transform the standard of care for autoimmune diseases and inflammation [3] - Updates will also be provided on the CUE-500 program, including CUE-501, which has been partnered with Boehringer Ingelheim to leverage anti-viral killer T cells for autoimmune diseases and cancer [3] Expert Contributions - Richard DiPaolo, PhD, is a leading expert in inflammation and immune regulation, with significant contributions to the understanding of regulatory T cells in autoimmunity [5] - Andrew Cope, MD, PhD, has extensive experience in rheumatology and is focused on chronic inflammatory diseases, including rheumatoid arthritis [6][7]